Abstract 126P
Background
Treatment of LARC has the main goal to achieve a tumor pathological complete response (pCR) that is strongly related to better disease-free survival (DFS) and overall survival (OS). However, it occurs only in 10-30% of LARC patients with neoadjuvant chemoradiotherapy (nCRT) with a high rate of distant metastasis (DM). TNT can improve patient’s outcomes by delivering systemic chemotherapy and nCRT prior to surgery. Multiple randomized trials (RAPIDO, PRODIGE 23, OPRA, CAO/ARO/AIO-12) evaluated different TNT strategies in terms of CRT sequencing, chemotherapy intensity, and radiotherapy. Overall, as a result from those trials, emerges that TNT increased pCR rate compared with standard nCRT (28,4% vs 14,3% RAPIDO and 27,5% vs 11,7% PRODIGE 23 and 28% vs 14% OPRA). However, there is lack of data about any difference in pathological response according to primary TH from anal verge and TNT.
Methods
This is a retrospective, multicentric, observational study whose aim is to evaluate the impact of TH from anal verge on pathological response (pR) to TNT in LARC through Ryan modified TRG score. Data were collected from 48 LARC patients (cT4N+), treated with induction mFOLFOX followed by long course nCRT and total mesorectal excision (TME). The secondary endpoint was ORR.
Results
The median age was 65 (± 8), 75% were male. All patients had clinical stage III. TH from anal verge were as follows 21% proximal (>10 cm), 46% middle (5-10 cm), and 33% (<5 cm) distal side. After TNT proximal cancers (PC) showed worst TRGs: TRG-4 (3 patients), TRG-3 (5 patients), and TRG-2 (2 patients). Middle cancers (MC) cancer showed: TRG-3 (1 patient), TRG-2 (11 patients), TRG1-0 (10 patients). Distal cancers (DC) showed: TRG2 (2 patients), TRG1-0 (13 patients). ORR was also different according to the TH: 30% PC, 77% for MC, and 80% for DC.
Conclusions
The results of our study show a correlation between rectal TH and responses to TNT. DCs seem to have a poorer pR to TNT. This data is consistent with recent literature about the actual usefulness of radiotherapy (RT) in patients with DCs and could help to a better selection of patients more suitable for TNT with or without RT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Pretta: Financial Interests, Personal, Speaker, Consultant, Advisor: Merck. All other authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract